More evidence that direct acting antiviral therapy is safe and effective in cirrhosis and chronic kidney disease including peritoneal dialysis

Clin Mol Hepatol. 2020 Oct;26(4):489-491. doi: 10.3350/cmh.2020.0228. Epub 2020 Sep 24.

Authors

Paul Kwo¹, Deepti Dronamraju¹

Affiliation

¹ Department of Gastroenterology and Hepatology, Stanford University, Redwood City, CA, USA.

No abstract available

Keywords: Antiviral agents; Hepatitis C; Liver cirrhosis; Peritoneal dialysis; Renal insufficiency, Chronic.

Publication types

Editorial
Comment

MeSH terms

Aminoisobutyric Acids
Antiviral Agents* / therapeutic use
Benzimidazoles
Cyclopropanes
Hepatitis C, Chronic* / complications
Hepatitis C, Chronic* / drug therapy
Humans
Lactams, Macrocyclic
Leucine / analogs & derivatives
Liver Cirrhosis / drug therapy
Peritoneal Dialysis*
Proline / analogs & derivatives
Pyrrolidines
Quinoxalines
Renal Insufficiency, Chronic* / complications
Renal Insufficiency, Chronic* / therapy
Sulfonamides

Substances

Aminoisobutyric Acids
Antiviral Agents
Benzimidazoles
Cyclopropanes
Lactams, Macrocyclic
Pyrrolidines
Quinoxalines
Sulfonamides
pibrentasvir
Proline
Leucine
glecaprevir